KRYS Krystal Biotech Inc Total Asset Value of Company

Krystal Biotech, Inc. (KRYS) maintains its resilience through clinic partnerships and the acquisition of bioplatforms. Monitoring total assets via ROA in a sideways trend confirms resource stability, where the value 1319.51 reflects the current magnitude. Growth is driven by unique gels for correcting genetic skin defects, while breakthrough direct gene delivery methods open the path to treating previously incurable pathologies.

KRYS (Krystal Biotech, Inc.) Company Total Assets history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Krystal Corp (KRYS)

- current quotes and average value forecast:

Market Chart krystalbio.com|KRYS - Price Target Chart

- market capitalization data:

Market Valuation Krystal Biotech Corp.|KRYS - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Krystal Biotech|KRYS - Book Capitalization|Market Capitalization to Book Value Ratio krystalbio.com|KRYS - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Krystal Biotech, Inc.|KRYS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Krystal Biotech Corp.|KRYS - Company Aggregate Debts|Debts to Book Capitalization Krystal Biotech Corp.|KRYS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Krystal Biotech|Interim Coverage Ratio krystalbio.com

- net income and valuation multiples indicators:

KRYS - Company Net Income

Fundamental valuation:Krystal Biotech, Inc.

Manufactured products of Krystal Biotech, Inc.

Total assets, reverse-calculated via ROA, reflect the aggregate value of Krystal Biotech, Inc. (KRYS) resources over time, neutralizing quarterly reporting time lags by accounting for currency fluctuations. By analyzing asset size through ROA, an investor can assess the financial resilience of Krystal Biotech, Inc. (KRYS) against logistical disruptions and sanction risks affecting component imports and the protection of foreign patents.

Key competitors

APGE - Company Total Asset Base|Aggregate Company Assets Arcutis Biotherapeutics, Inc.|Vericel Corp - Total Asset Value of Company|Company Total Assets ORKA|SMTI (sanaramedtech.com) - Aggregate Asset Value|Company Total Assets DBVT (DBV Technologies)|Company Total Assets Solesence Beauty SLSN|DERM - Aggregate Company Assets|Aggregate Asset Value FBRX (Forte Biosciences Inc.)|Empro (EMPG) - Aggregate Company Assets|Cumulative Company Assets Sol-Gel Technologies, Ltd.|AXIL (AXIL Brands Inc) - Company Total Assets|Company Total Assets medicuspharma.com|Cumulative Company Assets VRCA (Verrica Pharmaceuticals)|HOTH (hoththerapeutics.com) - Aggregate Asset Value|Aggregate Company Assets Biofrontera BFRI|Company Total Asset Base VYNE Therapeutics, Inc. (VYNE)|SNOA - Aggregate Company Assets|QNRX - Company Total Assets|AZTR: Company Total Assets|DRMA - Company Total Asset Base|Aggregate Company Assets Elevai Skincare|Total Business Assets RVNC (Revance Therapeutics Inc)